As per Washington state guidance, masks are required regardless of vaccination status in all of our facilities. Please be aware that if you do not have a mask when you arrive we can provide one for you or reschedule your appointment. We appreciate your understanding!

Gossamer

Double-blind, placebo-controlled, study to evaluate GB004 in adults with mild-to-moderate active UC

  • GB004 (formerly AKB-4924) is a HIF-1α stabilizer as an oral therapeutic, gut-targeted treatment for UC with higher intestinal than systemic exposure.
  • Randomized 1:1:1 to receive GB004 - 480mg BID / 480 mg QD / Placebo
  • 12 weeks double-blind treatment followed by 24 weeks of open label.
  • Currently receiving treatment for UC, on a stable dose for at least 2 weeks prior to flexible sigmoidoscopy or colonoscopy, with oral 5-ASA (eg, mesalamine, sulfasalazine) alone or with one of the following oral treatments:
  • a. prednisone ≤ 20 mg/day or equivalent or
    b. beclomethasone ≤ 5 mg/day or
    c. budesonide or budesonide multi-matrix (MMX) of ≤ 9 mg/day

17 Locations Focused on Serving Your Needs

Email us at [email protected]